紫鑫藥業(002118.SZ):控股股東康平公司所持1.32億股被司法拍賣
格隆匯 8 月 3日丨紫鑫藥業(002118.SZ)公告,近日,公司收到康平公司通知,因之前合同糾紛案,康平公司收到延邊朝鮮族自治州中級人民法院下達的《執行裁定書》。延邊朝鮮族自治州中級人民法院將於2020年8月31日10時至2020年9月1日10時止(延時除外)在延邊朝鮮族自治州中級人民法院阿里巴巴司法拍賣網絡平台上進行公開拍賣活動(法院賬户名:延邊朝鮮族自治州中級人民法院,法院主頁網址:sf.taobao.com/0433/13)進行公開拍賣活動,將公開拍賣康平公司所持有的合計1.3236億股公司股票,目前處於拍賣公示期。本次涉及股份數量合計132,360,000股,佔公司總股本比例10.33%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.